Nav: Home

ASCO18: Trial shows how PET scans help tailor therapy for esophageal cancer

June 03, 2018

Survival results for the CALGB 80303 Trial presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 demonstrate that esophageal cancer patients shown by PET scan to be non-responders to induction chemotherapy, and were then switched to a new chemotherapy during chemoradiation, showed median overall survival of 27 months. This improves on 18-month median overall survival of previous studies that used the same chemotherapy with non-responders during induction and chemoradiation treatment phases. Patients who were shown by PET to be responders to induction chemotherapy with the regimen FOLFOX and then stayed on FOLFOX during chemoradiation showed 55 percent 4-year survival, the best ever outcome reported for patients with this disease.

"Esophageal cancer patients undergo treatments to shrink tumors before surgery. We wanted to see if PET scan could help us personalize the best pre-operative treatment," says Karyn Goodman, MD, MS, Grohne Chair of Clinical Oncology at University of Colorado Cancer Center, and the national study chair of the CALGB 80303 Trial.

Currently, patients with stage II/III esophageal and gastroesophageal cancers typically receive 5.5 weeks of chemotherapy with radiation (chemoradiation) followed by surgery. Chemoradiation before surgery has been shown to improve survival compared with surgery alone, but the optimal chemotherapy for this patient population remains unknown.

The goal of the CALGB 80303 trial was to determine whether PET scan at baseline and then again after a short course of "induction chemotherapy" prior to chemoradiation could show which patients responded to the prescribed chemotherapy regimen, allowing responders to confidently continue the regimen that was working, while helping non-responders switch to the other chemotherapy regimen during chemoradiation.

In all, 257 U.S. patients with adenocarcinoma of the esophagus or gastroesophageal junction received PET scan at the time of diagnosis and again after six weeks of induction chemotherapy with either FOLFOX or carboplatin/taxol.

"If there was a good response by PET, they continued on the same chemotherapy during chemoradiation. If they had a poor response, they switched over to the alternative chemotherapy agent during chemoradiation," Goodman says.

After six weeks of chemoradiation including the same or the other chemotherapy regimen, patients underwent surgery, and then researchers followed their survival outcomes. Last year at ASCO 2017, Goodman and colleagues reported that changing chemotherapy regimen for non-responders increased the rate of pathologic complete response, meaning, "there were no traces of cancer in the tissue specimen taken at the time of surgery," Goodman says. This year at ASCO, researchers present survival data in this same population.

Overall, median survival remained higher in the group of patients that responded to induction chemotherapy than in the group that did not respond to induction therapy, at 46 months for responders and 27 months for non-responders.

"This makes sense," Goodman says. "Again, these are patients who benefitted from induction chemotherapy, whether with FOLFOX or with carboplatin/taxol. We would expect them to live longer than patients who did not respond."

In fact, it was impossible to accurately determine the median overall survival for patients who responded to FOLFOX during induction and then stayed on FOLFOX during chemoradiation, because more than half of these patients were still alive at the time of data analysis (the 55 percent 4-year survival listed above).

But the major update in outcomes was seen for patients who did not respond to induction treatment, and then switched to the other chemotherapy regimen during chemoradiation.

"Twenty-seven months median overall survival is much better than we have seen in previous studies for patients who do not respond to induction chemotherapy," Goodman says. "We show that using PET scan at baseline and then again after induction chemotherapy can help to determine who should stick with the chemotherapy used during induction and who should switch to the other regimen during chemoradiation."
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at Radiolab.org/donate.